Abstract:Randomised controlled trials and other prospective clinical studies for novel medical interventions in people with diabetes have traditionally reported HbA1c as the measure of average blood glucose levels for the 3 months preceding the HbA1c test date. The use of this measure highlights the long-established correlation between HbA1c and relative risk of diabetes complications; the change in the measure, before and after the therapeutic intervention, is used by regulators for the approval of medications for diabetes. However, with the increasing use of continuous glucose monitoring (CGM) in clinical practice, prospective clinical studies are also increasingly using CGM devices to collect data and evaluate glucose profiles among study participants, complementing HbA1c findings, and further assess the effects of therapeutic interventions on HbA1c. Data is collected by CGM devices at 1-5 min intervals, which obtains data on glycaemic excursions and periods of asymptomatic hypoglycaemia or hyperglycaemia (ie, details of glycaemic control that are not provided by HbA1c concentrations alone that are measured continuously and can be analysed in daily, weekly, or monthly timeframes). These CGM-derived metrics are the subject of standardised, internationally agreed reporting formats and should, therefore, be considered for use in all clinical studies in diabetes. The purpose of this consensus statement is to recommend the ways CGM data might be used in prospective clinical studies, either as a specified study endpoint or as supportive complementary glucose metrics, to provide clinical information that can be considered by investigators, regulators, companies, clinicians, and individuals with diabetes who are stakeholders in trial outcomes. In this consensus statement, we provide recommendations on how to optimise CGM-derived glucose data collection in clinical studies, including the specific glucose metrics and specific glucose metrics that should be evaluated. These recommendations have been endorsed by the American Association of Clinical Endocrinologists, the American Diabetes Association, the Association of Diabetes Care and Education Specialists, DiabetesIndia, the European Association for the Study of Diabetes, the International Society for Pediatric and Adolescent Diabetes, the Japanese Diabetes Society, and the Juvenile Diabetes Research Foundation. A standardised approach to CGM data collection and reporting in clinical trials will encourage the use of these metrics and enhance the interpretability of CGM data, which could provide useful information other than HbA1c for informing therapeutic and treatment decisions, particularly related to hypoglycaemia, postprandial hyperglycaemia, and glucose variability.

Q-Score Complements the Time in Range in the Evaluation of Short-Term Glycemic Control

Time in Range from Continuous Glucose Monitoring: A Novel Metric for Glycemic Control

A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings

Development of a three-dimensional scoring model for the assessment of continuous glucose monitoring data in type 1 diabetes

Carbohydrate counting knowledge and ambulatory glucose profile in persons living with type 1 diabetes

Establishment and Validation of GV-SAPS II Scoring System for Non-Diabetic Critically Ill Patients

Time in tight range: A key metric for optimal glucose control in the era of advanced diabetes technologies and therapeutics

Impact of glucose variability on the assessment of the glycemia risk index (GRI) and classic glycemic metrics

Relationship between key continuous glucose monitoring-derived metrics and specific cognitive domains in patients with type 2 diabetes mellitus

The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c

Author Response for "time in Tight Range: A Key Metric for Optimal Glucose Control in the Era of Advanced Diabetes Technologies and Therapeutics"

Glycemic Risk Index in a Cohort of Patients with Type 1 Diabetes Mellitus Stratified by the Coefficient of Variation: A Real-Life Study

Association between continuous glucose monitoring metrics and clinical outcomes in adults with type 1 diabetes in a real-world setting

The Glucose Management Indicator: Time to Change Course?

Characteristics of Glycemic Stability in Subjects with Different Glucose Tolerance: the Results of Continuous Glucose Monitoring

Continuous glucose monitoring and metrics for clinical trials: an international consensus statement

Comparison of Multiple Cut Points for Time in Range in Relation to Risk of Abnormal Carotid Intima-Media Thickness and Diabetic Retinopathy

Comparison of Points in Range Measured by the Self-monitoring of Blood Glucose and Time in Range Measured by the Continuous Glucose Monitoring

Time in Range, As a Novel Metric of Glycemic Control, is Reversely Associated with Presence of Diabetic Cardiovascular Autonomic Neuropathy Independent of HbA1c in Chinese Type 2 Diabetes

The glucogram: A new quantitative tool for glycemic analysis in the surgical intensive care unit

Flash Glucose Monitoring System Help Reduce the Frequency of Hypoglycemia and Hypoglycemic Fear Behavior in Type 1 Diabetes Patients